Key statistics
On Friday, Vaxcyte Inc (PCVX:NSQ) closed at 61.74, -21.60% below its 52-week high of 78.75, set on Feb 27, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 59.20 |
|---|---|
| High | 61.80 |
| Low | 59.03 |
| Bid | 57.61 |
| Offer | 62.96 |
| Previous close | 60.00 |
| Average volume | 1.29m |
|---|---|
| Shares outstanding | 143.92m |
| Free float | 142.98m |
| P/E (TTM) | -- |
| Market cap | 8.89bn USD |
| EPS (TTM) | -5.63 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $550 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
- Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
- Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
More ▼
